Ginkgo Bioworks (DNA) officer to sell 330 shares for taxes after vesting

Rhea-AI Filing Summary

Ginkgo Bioworks Holdings, Inc. (DNA) reports that officer Steven P. Coen has filed a notice of proposed sale of Class A common stock under Rule 144 through Fidelity Brokerage Services LLC. The notice covers 330 shares, tied to restricted stock vesting classified as compensation, with an indicated value of $2,302.47. The notice also lists a prior sale of 752 Class A shares on July 17, 2026 for $5,943.28. A remark states the sale includes an amount necessary to cover a tax obligation from the settlement of a vested equity award distribution.

Key Figures

Shares to be sold: 330 shares Proposed sale value: $2,302.47 Shares outstanding reference: 55,383,808 shares +4 more

7 metrics

Shares to be sold 330 shares Class A, proposed sale under Rule 144

Proposed sale value $2,302.47 Value listed for the 330 Class A shares

Shares outstanding reference 55,383,808 shares Class A figure shown in securities information

Prior 3-month sale shares 752 shares Class A shares sold on 07/17/2026

Prior 3-month sale value $5,943.28 Proceeds for 752 Class A shares on 07/17/2026

Date of notice 08/24/2026 Date of Rule 144 notice

Restricted stock vesting date 08/21/2026 Date tied to restricted stock vesting

Key Terms

Rule 144, restricted stock vesting, vested equity award distribution, compensation, +1 more

5 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock vesting financial

"Class A | 08/21/2026 | Restricted Stock Vesting | Issuer"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

vested equity award distribution financial

"resulting from the settlement of a vested equity award distribution."

compensation financial

"330 | 08/21/2026 | Compensation"

attorney-in-fact regulatory

"as attorney-in-fact for Steve Coen."

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What insider transaction is disclosed for Ginkgo Bioworks (DNA)?

Officer Steven P. Coen filed a Rule 144 notice to sell 330 Class A shares of Ginkgo Bioworks Holdings, Inc., related to restricted stock vesting and classified as compensation, with an indicated value of $2,302.47 through Fidelity Brokerage Services LLC.

How many Ginkgo Bioworks (DNA) shares are covered by the new Rule 144 notice?

The notice covers 330 Class A shares of Ginkgo Bioworks Holdings, Inc. These shares are linked to restricted stock vesting from the issuer and are categorized as compensation.

What prior Ginkgo Bioworks (DNA) share sale is reported for the past 3 months?

The document reports that 752 Class A shares were sold on 07/17/2026 for $5,943.28 for the account of Steve Coen.

What is the stated purpose of part of the Ginkgo Bioworks (DNA) sale?

The remarks state that the sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.

What share count for Ginkgo Bioworks (DNA) is referenced in the notice?

The notice references 55,383,808 Class A shares, listed in the securities information section. This figure appears alongside the proposed Rule 144 sale details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/24/2026 - 03:33 PM Accepted by SEC EDGAR 08/24/2026 - 03:32 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001977441
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Ginkgo Bioworks Holdings, Inc.
SEC File Number	001-40097
Address of Issuer	27 DRYDOCK AVENUE 8TH FLOOR BOSTON MASSACHUSETTS 02210
Phone	(877) 442-5362
Name of Person for Whose Account the Securities are To Be Sold	Coen Steven P.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	330	2302.47	55383808	08/24/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A	08/21/2026	Restricted Stock Vesting	Issuer			330	08/21/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Steve Coen 27 Drydock Avenue 8th Floor Boston MA 02210	Class A	07/17/2026	752	5943.28

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	08/24/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Joshua Schmitt, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Steve Coen.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)